CKD: Dapagliflozin Offers Benefits Regardless of Diabetes Status

Sarfaroj Khan 

Disclosures

January 22, 2021

Takeaway

  • Dapagliflozin lowers the risks of major adverse kidney and cardiovascular (CV) events and all-cause mortality in patients with chronic kidney disease (CKD), regardless of type 2 diabetes (T2D) status.

  • These benefits also extend to patients with a broad range of underlying causes of CKD other than diabetic nephropathy (DN), including those with primary glomerulonephritides and ischaemic or hypertensive kidney disease.

Why this matters

  • Dapagliflozin may provide substantial cardiorenal benefit to a broad range of patients with impaired kidney function and proteinuria, including patients with non-diabetic CKD.

Study design

  • In DAPA-CKD trial, 4304 patients with an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio of 200-5000 mg/g were randomly assigned (1:1) to receive dapagliflozin or placebo in addition to standard of care.

  • This prespecified analysis of the DAPA-CKD trial investigated whether the presence or absence of T2D at baseline and the underlying aetiology of kidney disease modified the effects of dapagliflozin.

  • Primary composite outcome: sustained ≥50% eGFR decline, end-stage kidney disease (ESKD) and renal or CV death.

  • Funding: AstraZeneca.

Key results

  • Overall, 2906 (68%) patients had T2D, of whom 396 (14%) had CKD attributed to causes other than DN.

  • Dapagliflozin reduced the risk of the primary composite outcome in patients with T2D (HR, 0.64; 95% CI, 0.52-0.79) and in those without T2D (HR, 0.50; 95% CI, 0.35-0.72; Pinteraction=.24).

  • Similar results were seen for the secondary outcomes in patients with T2D vs those without:

    • sustained ≥50% eGFR decline, ESKD and renal death (HR, 0.57; 95% CI, 0.45-0.73 vs HR, 0.51; 95% CI, 0.34-0.75; Pinteraction=.57);

    • CV death or hospitalisation for HF (HR, 0.70; 95% CI, 0.53-0.92 vs HR, 0.79; 95% CI, 0.40-1.55; Pinteraction=.78); and

    • all-cause mortality (HR, 0.74; 95% CI, 0.56-0.98 vs HR, 0.52; 95% CI, 0.29-0.93; Pinteraction=.25).

  • The effect of dapagliflozin on the primary outcome was consistent in patients with DN (HR, 0.63; 95% CI, 0.51-0.78), glomerulonephritides (HR, 0.43; 95% CI, 0.26-0.71), ischaemic or hypertensive CKD (HR, 0.75; 95% CI, 0.44-1.26) and CKD of other or unknown causes (HR, 0.58; 95% CI, 0·29-1·19; Pinteraction=.53), with similar consistency seen across the secondary outcomes.

Limitations

  • T2D diagnosis was based on investigator-reported diagnosis or glycated haemoglobin values and not on more conventional tests.

 

Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PMID: 33338413 View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....